Use of FeNO to predict anti-IL-5 and IL-5R biologics efficacy in a real-world cohort of adults with severe eosinophilic asthma

References

• Schleich F, Brusselle G, Louis R, Vandenplas O, Michils A, Pilette C, Peche R, Manise M, Joos G. Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). Respir Med. 2014;108(12):1723–1732. doi:10.1016/j.rmed.2014.10.007.
   PubMed Web of Science ®Google Scholar
• Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi:10.1183/09031936.00202013.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention. [accessed 2022 January 17). https://ginasthma.org/gina-reports/.
   Google Scholar
• Kerkhof M, Tran TN, Soriano JB, Golam S, Gibson D, Hillyer EV, Price DB. Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population. Thorax. 2018;73(2):116–124. doi:10.1136/thoraxjnl-2017-210531.
   PubMed Web of Science ®Google Scholar
• Chibana K, Trudeau JB, Mustovich AT, Mustovitch AT, Hu H, Zhao J, Balzar S, Chu HW, Wenzel SE. IL-13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells. Clin Exp Allergy. 2008;38(6):936–946. doi:10.1111/j.1365-2222.2008.02969.x.
   PubMed Web of Science ®Google Scholar
• Berry MA, Shaw DE, Green RH, Brightling CE, Wardlaw AJ, Pavord ID. The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma. Clin Exp Allergy. 2005;35(9):1175–1179. doi:10.1111/j.1365-2222.2005.02314.x.
   PubMed Web of Science ®Google Scholar
• Mattes J, Storm van’s Gravesande K, Reining U, Alving K, Ihorst G, Henschen M, Kuehr J. NO in exhaled air is correlated with markers of eosinophilic airway inflammation in corticosteroid-dependent childhood asthma. Eur Respir J. 1999;13(6):1391–1395.
   PubMed Web of Science ®Google Scholar
• Strunk RC, Szefler SJ, Phillips BR, Zeiger RS, Chinchilli VM, Larsen G, Hodgdon K, Morgan W, Sorkness CA, Lemanske RF.Jr. Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute Relationship of exhaled nitric oxide to clinical and inflammatory markers of persistent asthma in children. J Allergy Clin Immunol. 2003;112(5):883–892. doi:10.1016/j.jaci.2003.08.014.
   PubMed Web of Science ®Google Scholar
• Jatakanon A, Lim S, Kharitonov SA, Chung KF, Barnes PJ. Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. Thorax. 1998;53(2):91–95. doi:10.1136/thx.53.2.91.
   PubMed Web of Science ®Google Scholar
• Wagener AH, de Nijs SB, Lutter R, Sousa AR, Weersink EJ, Bel EH, Sterk PJ. External validation of blood eosinophils, FENO and serum periostin as surrogates for sputum eosinophils in asthma. Thorax. 2015;70(2):115–120. doi:10.1136/thoraxjnl-2014-205634.
   PubMed Web of Science ®Google Scholar
• Kimura H, Konno S, Makita H, Taniguchi N, Shimizu K, Suzuki M, Kimura H, Goudarzi H, Nakamaru Y, Ono J, Hi-CARAT investigators, et al. Prospective predictors of exacerbation status in severe asthma over a 3-year follow-up. Clin Exp Allergy. 2018;48(9):1137–1146. doi:10.1111/cea.13170.
   PubMed Web of Science ®Google Scholar
• Mansur AH, Srivastava S, Sahal A. Disconnect of type 2 biomarkers in severe asthma; dominated by FeNO as a predictor of exacerbations and periostin as predictor of reduced lung function. Respir Med. 2018;143:31–38. doi:10.1016/j.rmed.2018.08.005.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659. doi:10.1016/S0140-6736(12)60988-X.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, MENSA Investigators, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. doi:10.1056/NEJMoa1403290.
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkstrom V, SIROCCO study investigators, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–2127. doi:10.1016/S0140-6736(16)31324-1.
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S, CALIMA study investigators, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141. doi:10.1016/S0140-6736(16)31322-8.
   PubMed Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–2496. doi:10.1056/NEJMoa1804092.
   PubMed Web of Science ®Google Scholar
• Reddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R, Cruz AA, Duijts L, Drazen JM, FitzGerald JM, et al. Global initiative for asthma strategy 2021: executive summary and rationale for key changes. Am J Respir Crit Care Med. 2022;205(1):17–35. doi:10.1164/rccm.202109-2205PP.
   PubMed Web of Science ®Google Scholar
• Hearn AP, Kavanagh J, d‘Ancona G, Roxas C, Green L, Thomson L, Fernandes M, Kent BD, Dhariwal J, Nanzer AM, et al. The relationship between Feno and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma. J Allergy Clin Immunol Pract. 2021;9(5):2093–2096 e1. doi:10.1016/j.jaip.2021.01.008.
   PubMed Web of Science ®Google Scholar
• Watanabe H, Shirai T, Hirai K, Akamatsu T, Nakayasu H, Tamura K, Masuda T, Takahashi S, Tanaka Y, Kishimoto Y, et al. Blood eosinophil count and FeNO to predict benralizumab effectiveness in real-life severe asthma patients. J Asthma. 2022;59(9):1796–1804. doi:10.1080/02770903.2021.1963769.
   Web of Science ®Google Scholar
• Culver BH, Graham BL, Coates AL, Wanger J, Berry CE, Clarke PK, Hallstrand TS, Hankinson JL, Kaminsky DA, MacIntyre NR, ATS Committee on Proficiency Standards for Pulmonary Function Laboratories, et al. Recommendations for a standardized pulmonary function report. An official American Thoracic Society technical statement. Am J Respir Crit Care Med. 2017;196(11):1463–1472. doi:10.1164/rccm.201710-1981ST.
   PubMed Web of Science ®Google Scholar
• Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, Olin AC, Plummer AL, Taylor DR, American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels for Clinical A. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602–615. doi:10.1164/rccm.9120-11ST.
   PubMed Web of Science ®Google Scholar
• Dweik RA, Sorkness RL, Wenzel S, Hammel J, Curran-Everett D, Comhair SA, Bleecker E, Busse W, Calhoun WJ, Castro M, National Heart, Lung, and Blood Institute Severe Asthma Research Program, et al. Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma. Am J Respir Crit Care Med. 2010;181(10):1033–1041. doi:10.1164/rccm.200905-0695OC.
   PubMed Web of Science ®Google Scholar
• Busse WW, Wenzel SE, Casale TB, FitzGerald JM, Rice MS, Daizadeh N, Deniz Y, Patel N, Harel S, Rowe PJ, et al. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. Lancet Respir Med. 2021;9(10):1165–1173. doi:10.1016/S2213-2600(21)00124-7.
   PubMed Web of Science ®Google Scholar
• Price DB, Bosnic-Anticevich S, Pavord ID, Roche N, Halpin DMG, Bjermer L, Usmani OS, Brusselle G, Ming SWY, Rastogi S. Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations. Clin Transl Allergy. 2019;9:41. doi:10.1186/s13601-019-0282-7.
   PubMed Web of Science ®Google Scholar
• Couillard S, Steyerberg E, Beasley R, Pavord I. Blood eosinophils, fractional exhaled nitric oxide and the risk of asthma attacks in randomised controlled trials: protocol for a systemic review and control arm patient-level meta-analysis for clinical prediction modelling. BMJ Open. 2022;12(4):e058215. doi:10.1136/bmjopen-2021-058215.
   PubMed Web of Science ®Google Scholar
• Bal C, Idzko M, Skrgat S, Koch A, Milger K, Schulz C, Zehetmayer S, Hamelmann E, Buhl R, Korn S. FeNO is associated with disease burden in the German Asthma Net severe asthma cohort. Eur Respir J. 2022;59(6):2101233. doi:10.1183/13993003.01233-2021.
   PubMed Web of Science ®Google Scholar
• Brusselle GG, Koppelman GH. Biologic therapies for severe asthma. N Engl J Med. 2022;386(2):157–171. doi:10.1056/NEJMra2032506.
   PubMed Web of Science ®Google Scholar
• Kavanagh JE, Hearn AP, Dhariwal J, d‘Ancona G, Douiri A, Roxas C, Fernandes M, Green L, Thomson L, Nanzer AM, et al. Real-world effectiveness of benralizumab in severe eosinophilic asthma. Chest. 2021;159(2):496–506. doi:10.1016/j.chest.2020.08.2083.
   PubMed Web of Science ®Google Scholar
• Yamada H, Nakajima M, Matsuyama M, Morishima Y, Arai N, Hida N, Nakaizumi T, Masuko H, Yatagai Y, Saito T, et al. Identification of distinct phenotypes related to benralizumab responsiveness in patients with severe eosinophilic asthma. PLoS One. 2021;16(3):e0248305. doi:10.1371/journal.pone.0248305.
   PubMed Web of Science ®Google Scholar
• Harvey ES, Langton D, Katelaris C, Stevens S, Farah CS, Gillman A, Harrington J, Hew M, Kritikos V, Radhakrishna N, et al. Mepolizumab effectiveness and identification of super-responders in severe asthma. Eur Respir J. 2020;55(5):1902420. doi:10.1183/13993003.02420-2019.
   PubMed Web of Science ®Google Scholar
• Shrimanker R, Keene O, Hynes G, Wenzel S, Yancey S, Pavord ID. Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide, and their combination in severe asthma: a post hoc analysis. Am J Respir Crit Care Med. 2019;200(10):1308–1312. doi:10.1164/rccm.201903-0599LE.
   PubMed Web of Science ®Google Scholar
• Katial R, Kreindler J, Hirsch I, Newbold P, Garcia Gil EG. Blood eosinophil count and fractional exhaled nitric oxide as a combined predictor of treatment response to benralizumab for patients with severe, eosinophilic asthma. Pneumologie. 2021;75(S 01):S34.
   Google Scholar
• Kavanagh JE, d’Ancona G, Elstad M, Green L, Fernandes M, Thomson L, Roxas C, Dhariwal J, Nanzer AM, Kent BD, et al. Real-world effectiveness and the characteristics of a “super-responder” to mepolizumab in severe eosinophilic asthma. Chest. 2020;158(2):491–500. doi:10.1016/j.chest.2020.03.042.
   PubMed Web of Science ®Google Scholar
• Schleich F, Graff S, Nekoee H, Moermans C, Henket M, Sanchez C, Paulus V, Guissard F, Donneau AF, Louis R. Real-world experience with mepolizumab: Does it deliver what it has promised? Clin Exp Allergy. 2020;50(6):687–695. doi:10.1111/cea.13601.
   PubMed Web of Science ®Google Scholar
• Busby J, Khoo E, Pfeffer PE, Mansur AH, Heaney LG. The effects of oral corticosteroids on lung function, type-2 biomarkers and patient-reported outcomes in stable asthma: a systematic review and meta-analysis. Respir Med. 2020;173:106156. doi:10.1016/j.rmed.2020.106156.
   PubMed Web of Science ®Google Scholar
• Comberiati P, Peroni D, Malka-Rais J, Morganti R, Spahn J. Fractional exhaled nitric oxide response to oral corticosteroids in children with mild-to-moderate asthma: influence of race. Ann Allergy Asthma Immunol. 2020;125(4):440–446.e1. doi:10.1016/j.anai.2020.06.036.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, Zhu H, Hamilton JD, Swanson BN, Khan A, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–2485. doi:10.1056/NEJMoa1804093.
   PubMed Web of Science ®Google Scholar
• Ramonell RP, Lee FE, Levy JM, Kuruvilla M. Exhaled nitric oxide measurements are not influenced by anti-eosinophil therapy in patients with asthma: a retrospective analysis. Ann Allergy Asthma Immunol. 2021;126(1):102–104. doi:10.1016/j.anai.2020.09.005.
   PubMed Web of Science ®Google Scholar
• Numata T, Nakayama K, Utsumi H, Kobayashi K, Yanagisawa H, Hashimoto M, Minagawa S, Ishikawa T, Hara H, Araya J, et al. Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis. BMC Pulm Med. 2019;19(1):176. doi:10.1186/s12890-019-0952-1.
   PubMed Web of Science ®Google Scholar
• Charles D, Shanley J, Temple SN, Rattu A, Khaleva E, Roberts G. Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: a systematic review and meta-analysis. Clin Exp Allergy. 2022;52(5):616–627. doi:10.1111/cea.14112.
   PubMed Web of Science ®Google Scholar
• Pelletier G, Godbout K, Boulay ME, Boulet LP, Morissette MC, Cote A. Increase in FeNO levels following IL5/IL5R-targeting therapies in severe asthma: a case series. J Asthma Allergy. 2022;15:691–701. doi:10.2147/JAA.S358877.
   PubMed Web of Science ®Google Scholar
• Fulkerson PC, Rothenberg ME. Targeting eosinophils in allergy, inflammation and beyond. Nat Rev Drug Discov. 2013;12(2):117–129. doi:10.1038/nrd3838.
   PubMed Web of Science ®Google Scholar
• Greenfeder S, Umland SP, Cuss FM, Chapman RW, Egan RW. Th2 cytokines and asthma. The role of interleukin-5 in allergic eosinophilic disease. Respir Res. 2001;2(2):71–79. doi:10.1186/rr41.
   PubMed Web of Science ®Google Scholar